Background
==========

The prevalence of total knee arthroplasty (TKA) is increasing, which is one of the most frequent operations in orthopedic practice \[[@b1-medscimonit-21-3095]\]. However, the considerable intraoperative and postoperative blood loss may be a trigger increasing risk of allogeneic blood transfusion, which causes subsequent complications, such as infections, intravascular hemolysis, and cardiopulmonary events \[[@b1-medscimonit-21-3095]--[@b3-medscimonit-21-3095]\]. Moreover, patients who underwent TKA are mostly aged people (65.7±8.2) \[[@b4-medscimonit-21-3095],[@b5-medscimonit-21-3095]\], whose ability to replace lost blood is insufficient to maintain health. Therefore, they are more vulnerable to series of transfusion reactions, and even death. Thus, an effective and safe way to decrease complications of blood transfusion is to suppress intraoperative and postoperative blood loss \[[@b4-medscimonit-21-3095],[@b5-medscimonit-21-3095]\].

Several methods had been applied for suppressing perioperative blood loss, including tourniquet, intraoperative blood salvage, and the application of antifibrinolytic agents \[[@b6-medscimonit-21-3095],[@b7-medscimonit-21-3095]\]. Antifibrinolytic agents are widely used and potentially interrupt the cascade of haemostatic abnormalities and enhance hemostasis \[[@b8-medscimonit-21-3095]\]. As a result, they may potentially reduce blood loss, blood transfusion, and transfusion reaction.

Tranexamic acid is a kind of synthetical antifibrinolytic agent, which blocks the activation of plasminogen to plasmin and blocks the fibrinolytic action of plasmin on fibrin. With the administration of TA, activation of plasminogen and fibrinolysis are both suppressed \[[@b9-medscimonit-21-3095],[@b10-medscimonit-21-3095]\]. TA can prevent clots and reduce blood loss. Topical and intravenous administration of TA has been applied in many surgical practices, including TKA, which not only could reduce topical blood loss but also inhibits plasmin-induced platelet activation to affect hemostasis of the cardiopulmonary system \[[@b9-medscimonit-21-3095]\].

More and more researchers have reported positive outcomes of administration of TA in TKA. However, the TA treatment administration varied among countries and surgeons. Several researchers have found that the use of TA could increase the risk of deep vein thrombosis and question the effectiveness and safety of TA \[[@b11-medscimonit-21-3095]\]. The goal of this analysis is to further investigate the safe and effective role of using tranexamic acid (TA) in reducing transfusion rate and blood loss in total knee arthroplasty.

Material and Methods
====================

This study was conducted in accordance with the guidelines described in the Cochrane Handbook for meta-analysis and also based on the recommended PRISMA checklist guidelines \[[@b12-medscimonit-21-3095]\].

Search strategy
---------------

We searched PubMed, Web of Science, and EMBASE from 1950 to June 2015 to identify relevant studies. The following selected Medical Subject Headings terms were used for the initial literature search: 'Anti-fibrinolytics' or 'Tranexamic acid' or 'Cyklokapron' and 'total knee replacement'or 'total knee arthroplasty'.

Criteria of eligibility
-----------------------

Studies were considered eligible if they met the following criteria: 1) patients underwent a primary TKA; 2) the experiment group was considered as the administration of intravenous TA and placebo or no treatment for control group; 3) outcome measures included total blood loss, blood transfusion rate, and incidence of thromboembolism complications; 4) randomized controlled trials and prospective comparative studies. Exclusion criteria: 1) allergy to TA; 2) bleeding disorders; 3) thromboembolic complications.

Data extraction
---------------

Eligible articles were reviewed independently by 2 investigators (Yu Xiao and Weili Li). The titles and abstracts of the references were read. Any disagreement on a controversial study was settled by discussion and consensus.

Quality assessment
------------------

The methodological quality of included studies was evaluated with a generic evaluation tool \[[@b13-medscimonit-21-3095]\]. The quality of each study was evaluated by a score from 0 to 24. Any disagreement on a controversial study was resolved by discussion and consensus.

Statistical analysis
--------------------

Continuous variables were indicted as mean standard deviation, and the outcomes were analyzed by mean difference with 95% confidence interval. Dichotomous variables for each arm were indicted as risks, and the outcomes were analyzed by a risk difference with 95% CI.

Heterogeneity was conducted using Cochran's Q test and Higgins I-squared statistic. Heterogeneity was defined as p\<0.10 or I^2^ \>50% \[[@b14-medscimonit-21-3095]\]. The random-effects model was used if heterogeneity was observed (P\<0.10), and the fixed-effects model was used in the absence of between-study heterogeneity (P\>0.1). All of the above calculations were performed using RevMan 5.2 (Cochrane collaboration, Oxford, UK) software.

Results
=======

Characteristics of the eligible studies
---------------------------------------

We initially found 409 studies in our search of PubMed, Web of Science, and EMBASE. With the review of these abstracts, 49 potentially relevant studies were identified as eligible for full-text review, and 34 RCTs met the inclusion criteria. Among them, 6 trials were further excluded because TA was administered through knee joint injection in 2 trials, and placebo or blank control group was not set in 2 trials. Finally, 28 studies \[[@b15-medscimonit-21-3095]--[@b41-medscimonit-21-3095]\] were identified according to the inclusion criteria of the meta-analysis ([Figure 1](#f1-medscimonit-21-3095){ref-type="fig"}) and detail information were displayed in [Table 1](#t1-medscimonit-21-3095){ref-type="table"}.

Total blood loss
----------------

Total blood loss was reported in 24 studies \[[@b15-medscimonit-21-3095]--[@b17-medscimonit-21-3095],[@b19-medscimonit-21-3095],[@b20-medscimonit-21-3095], [@b22-medscimonit-21-3095]--[@b29-medscimonit-21-3095],[@b30-medscimonit-21-3095]--[@b33-medscimonit-21-3095],[@b35-medscimonit-21-3095]--[@b42-medscimonit-21-3095]\]. Total blood loss was dramatically decreased via the application of TA by a mean of 420 ml \[95% CI: −514 to −327, P\<0.00001\]. However, significant heterogeneity (I^2^=90%) among included studies was detected, so the random-effects model was used. Based on data (420 ml \[95% CI: −514 to −327, P\<0.00001\]) displayed in [Figure 2A](#f2-medscimonit-21-3095){ref-type="fig"}, we conclude that total blood loss volume decreased sharply with the use of TA in TKA.

Blood transfusion rate
----------------------

Blood transfusions were recorded in 26 trials \[[@b15-medscimonit-21-3095]--[@b26-medscimonit-21-3095],[@b28-medscimonit-21-3095],[@b30-medscimonit-21-3095]--[@b42-medscimonit-21-3095]\] including 2410 patients. Among them, there were 172 patients who took TA and 318 patients who took placebo who needed transfusion. TA significantly reduced the number of patients who needed transfusion \[P\<0.01, RD=−0.26, 95% CI −0.33 to −0.19\]. Heterogeneity existed between trials \[P\<0.01, I^2^=80%\]. As shown in [Figure 2B](#f2-medscimonit-21-3095){ref-type="fig"} (\[P\<0.01, RD=−0.26, 95% CI −0.33 to −0.19\]), TA can also reduce the blood transfusion rate of patients who underwent TKA.

Postoperative drainage
----------------------

Fifteen studies (997 patients) reported postoperative drainage \[[@b15-medscimonit-21-3095],[@b19-medscimonit-21-3095],[@b20-medscimonit-21-3095],[@b24-medscimonit-21-3095]--[@b29-medscimonit-21-3095],[@b31-medscimonit-21-3095],[@b33-medscimonit-21-3095],[@b38-medscimonit-21-3095],[@b40-medscimonit-21-3095]--[@b42-medscimonit-21-3095]\]. The application of TA significantly decreased postoperative drainage \[MD: −275.47 mL, 95% CI −362.64 to −188.30; P\<0.00001\]. There was significant heterogeneity \[P\<0.00001; I^2^=94%\]. The TA group had less postoperative drainage compared to the control group ([Figure 3](#f3-medscimonit-21-3095){ref-type="fig"}).

Incidence of DVT
----------------

In 26 trials \[[@b15-medscimonit-21-3095]--[@b20-medscimonit-21-3095],[@b22-medscimonit-21-3095]--[@b30-medscimonit-21-3095],[@b32-medscimonit-21-3095]--[@b42-medscimonit-21-3095]\], data on DVT were available. Studies included 919 and 877 patients in the TA group and control group, respectively. Among them, 22 patients in the TA group and 20 in the control group developed DVT. There was no statistically significant difference between TA and control groups (P=0.91) and no heterogeneity between trials (P=1.00, I^2^=0) ([Figure 4A](#f4-medscimonit-21-3095){ref-type="fig"}).

Incidence of PE
---------------

In 15 trials, data were available on patient outcomes \[[@b16-medscimonit-21-3095]--[@b19-medscimonit-21-3095], [@b23-medscimonit-21-3095],[@b25-medscimonit-21-3095]--[@b27-medscimonit-21-3095],[@b30-medscimonit-21-3095],[@b32-medscimonit-21-3095],[@b33-medscimonit-21-3095],[@b35-medscimonit-21-3095],[@b37-medscimonit-21-3095]--[@b39-medscimonit-21-3095],[@b42-medscimonit-21-3095]\]. In the TA group, no PE was reported. In the control group, 3 patients out of 550 developed PE. There was no statistically significant difference in the risk of developing PE between TA and control groups (P=0.47). There was no heterogeneity between trials (P=1.00, I^2^=0) ([Figure 4B](#f4-medscimonit-21-3095){ref-type="fig"}).

Discussion
==========

The results of the study demonstrate that the application of TA could significantly reduce total blood loss, allowing patients to benefit from it more. Moreover, the number of patients who needed to receive allogeneic transfusions in TKA was dramatically decreased with the application of TA. This study demonstrated that use of TA did not increase the incidence of DVT or PE. However, significant heterogeneity was detected between trials. Many factors may lead to the existence of heterogeneity, such as different types of anesthesia, surgical techniques, or TA use. The reasons for high heterogeneity may be that hidden bleeding was rarely measured or that different times of extraction of the drain tube were reported.

Among all antifibrinolytic agents, TA is not the only agent used in TKA. Other antifibrinolytic agents include fibrin spray, epsilon aminocaproic acid, and aprotinin, which have been used to decrease surgical blood loss \[[@b43-medscimonit-21-3095]\]. However, some defects had been detected via clinical observations. These antifibrinolytic agents had been shown to be more costly and less effective than TA \[[@b44-medscimonit-21-3095]\]. TA could bring better penetration into major joints than fibrin spray and it is less expensive and safer than aprotinin and more effective than EACA. The binding of TA to plasminogen is 6 to 10 times more potent than that of EACA \[[@b45-medscimonit-21-3095]\].

Because of activation of fibrinolysis and the exposed surface of cancellous bone, TKA could cause significant blood loss. Here, the most noteworthy result of this study was the efficiency of TA in reducing total blood loss and transfusion rates after TKA. Our study indicates that intravenous use of TA results in sparing at a mean of 420 ml of total blood loss and significantly reduced transfusion rates. At the same time, the use of TA could effectively reduce postoperative drainage volume. Because of occurrence of the occasional thromboembolism events, some physicians are reluctant to use TA in TKA. However, the safety of TA could further be confirmed with the help of our study. In our study, 22 patients in the TA group and 20 patients in the control group developed DVT, with no significant difference (P=0.91). Only 3 patients developed PE events and they all belonged to the control group. The difference between TA and control group was also not statistically significant (P=0.47). With the evidence collected, TA did not increase risks of DVT or PE. Tourniquet use is common in TKA, which activates the local fibrinolysis system and significantly increases blood loss after surgery. TA has antifibrinolytic potency via blocking the lysine-binding sites of plasminogen and is mostly used in bleeding caused by local accentuation of fibrinolysis. On this point, TA mainly resists the fibrinolysis effect caused by tourniquet and generally has little influence on the normal fibrinolysis system. These results are consistent with other meta-analyses \[[@b46-medscimonit-21-3095],[@b47-medscimonit-21-3095]\]. The major contraindication to administering TA is allergy. Because high doses of TA might increase the incidence of thrombosis, it is not recommended in patients who have PE history or state. Poeran \[[@b48-medscimonit-21-3095]\] reported that patients who received TA had lower rates of blood transfusion (7.7 *vs.* 20.1%) as well as combined complications (1.9 *vs.* 2.6%). With an increasing dose of TXA (0--1 g, 1--2 g and \>3 g), odds (OR: 0.31 to 0.38) of blood transfusion decreased and risk of complications did not increase significantly.

In our study, most of the trials were of high quality (QAS: 19--24), which makes the conclusions drawn from this meta-analysis more reliable, but there are still many limitations in our analysis: (I) Some uncontrolled factors among the studies may have accounted for the significant heterogeneity in total blood loss, transfusion requirements, and drain loss. (II) We selected studies that excluded high-risk patients, including patients with cardiovascular disorders, and DVT events. Thus, our results should be interpreted with caution.

Conclusions
===========

This meta-analysis concludes that TA significantly reduces total blood loss and transfusion rate after TKA and does not apparently increase the risk of DVT or PE. Lager-scale prospective randomized controlled studies are needed and the optimal administration of TA in TKA still needs further investigation. Moreover, to better highlight the safety and efficacy of TA in TKA, studies that compare TA with other anti-fibrinolytics are needed.
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###### 

Characteristics of included studies.

  Author, year             Cases      Intervention                                                                     Control   DVT prophylaxis     Blood transfusion   DVT screening method       QAS
  ------------------------ ---------- -------------------------------------------------------------------------------- --------- ------------------- ------------------- -------------------------- -----
  Alvarez 2008             95 (46)    10 mg/kg 30 min before tourniquet deflation, 1 mg/kg/h infusion for 6 h          S         Bemiparin           Hb \<90 g/L         Clinical exam              23
  Benoni 1996              86 (43)    10 mg/kg before tourniquet deflation, 10 mg/kg after 3 h                         S         LMWH                Hb \<85 g/L         Clinical exam              23
  Camarasa 2006            95 (35)    10 mg/kg before tourniquet deflation, repeated 3 h later                         S         Dalteparin sodium   Hb \<80 g/L         Clinical exam/ultrasound   23
  Chareancholvanich 2012   120 (60)   10 mg/kg 10 min before tourniquet deflation, then 10 mg/kg 3 h postoperatively   NA        Ankle motion        Hb \<100 g/L        Clinical exam              21
  Charoencholvanich 2011   100 (50)   10 mg/kg 10 min before tourniquet deflation, repeated 3 h later                  S         Ankle motion        Hb \<100 g/L        Clinical exam              21
  Dhillon 2011             108 (52)   10 mg/kg IV 10 min tourniquet deflation and after 3 h                            NA        LMWH                Hb \<90 g/L         Clinical exam              22
  Ellis 2001               20 (10)    15 mg/kg 30 min before tourniquet deflation, 10 mg/kg/h infusion for 12h         S         Enoxaparin          Hct \<27%           NA                         24
  Engel 2001               24 (12)    15 mg/kg before tourniquet deflation, 10 mg/kg after 3 h                         NA        Certoparin          Hb \<100 g/L        Clinical exam              21
  Gautam 2011              40 (20)    10 mg/kg 0.5 h before tourniquet deflation, 2 mg/kg after 3 h                    S         NA                  Hb \<80 g/L         Clinical exam              20
  Good 2003                51 (27)    10 mg/kg before tourniquet deflation, repeated 3 h later                         S         Fragmin             Hb \<90 g/L         Clinical exam/ultrasound   20
  Hiippala 1995            28 (15)    15 mg/kg before tourniquet deflation                                             NS        LMWH                Hb \<100 g/L        Clinical exam              23
  Hiippala 1997            77 (39)    15 mg/kg before tourniquet deflation, additional doses of 10 mg/kg after 3h      S         Enoxaparin          Hb \<100 g/L        Clinical exam              23
  Ido 2000                 43 (21)    1 g before tourniquet release,1 g 3 h after operation                            NA        NA                  NA                  Clinical exam              19
  Jansen 1999              42 (21)    15 mg/kg 30 min before tourniquet deflation, repeated every 8 h for 3 d          S         Fraxiparine         PCV \<26%           Clinical exam              21
  Kakar 2009               24 (12)    10 mg/kg before tourniquet deflation, 1 mg/kg/h until wound closure              NS        NA                  Hb \<80 g/L         NA                         23
  Lee 2012                 72 (36)    10 mg/kg before tourniquet deflation, repeated 6 h later                         NA        LMWH                Hb \<80 g/L         Clinical exam/ultrasound   20
  Lin 2011                 100 (50)   10 mg/kg IV before deflation of the tourniquet                                   S         LMWH                Hb \<85 g/L         NA                         18
  MacGillivray 2011        60 (20)    10--15 mg/kg tourniquet deflation and after 3 h                                  NS        Warfarin            Hb \<80 g/L         Clinical exam/CT           24
  Maniar 2012              80 (40)    10 mg/kg IV before deflation of the tourniquet                                   S         LMWH                Hb \<85 g/L         Clinical exam              22
  McConnell 2012           44 (22)    10 mg/kg at induction of anesthesia                                              NA        Aspirin             NA                  Clinical exam              20
  Molloy 2007              100 (50)   500 mg 5 min before tourniquet deflation, repeated 3 h later                     NA        Aspirin             Hct \<25%           Clinical exam              23
  Orpen 2006               29 (15)    15 mg/kg at cement mixing commenced                                              NS        Fragmin             Hb \<90 g/L         ultrasound                 23
  Seo 2013                 100 (50)   1.5g TXA/100mL NS                                                                S         NA                  Hb \<80 g/L         NA                         19
  Shen 2015                96 (46)    100 mL,15 min before tourniquet deflation                                        S         LMWH                Hb \<80 g/L         ultrasound                 22
  Tanaka 2001              99 (73)    10 mg/kg before surgery, 10 mg/kg 10 min before tourniquet deflation             S         NA                  NA                  Venography                 19
  Veien 2002               30 (15)    10 mg/kg before tourniquet deflation, repeated 3 h later                         NS        Fraxiparine         Hct \<28%           Clinical exam              22
  Zhang 2007               102 (51)   1 g before tourniquet deflation, repeated 3 h later                              S         LMWH                NA                  Clinical exam              19
  Zohar 2004               40 (20)    15 mg/kg 15 min before tourniquet deflation,10 mg/kg/h infusion for 12h          NA        Enoxaparin          Hct \<28%           Clinical exam/ultrasound   21

NA -- not available; S -- saline; NS -- normal saline; LMWH -- low-molecular-weight heparin; QAS -- quality assessment score.
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